极长链酰基辅酶A脱氢酶缺乏症
Very long chain acyl-CoA dehydrogenase deficiency
定义 英文原文（暂无中文）
Very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency (VLCADD) is an inherited disorder of mitochondrial long-chain fatty acid oxidation with a variable presentation including: cardiomyopathy, hypoketotic hypoglycemia, liver disease, exercise intolerance and rhabdomyolysis.
别名
VLCAD 缺乏症
基本事实
- 遗传方式
- 常染色体隐性
- 发病年龄
- 婴儿期、新生儿期
- 患病率
- 1-9 / 100 000（Europe）
相关基因 1
| 基因 | 名称 | 关联类型 |
|---|---|---|
| ACADVL | acyl-CoA dehydrogenase very long chain | Disease-causing germline mutation(s) in |
临床表型 40
常见 79–30%1
- 循环系统内游离脂肪酸水平增高 HP:0030781
偶见 29–5%15
- 房间隔缺损 HP:0001631
- 血清肌酸磷酸激酶升高 HP:0003236
- 循环肝转氨酶水平升高 HP:0002910
- 阵发性呼吸急促 HP:0002876
- 运动诱发的横纹肌溶解 HP:0009045
- 喂养困难 HP:0011968
- 肝脏肿大 HP:0002240
- 低酮性低血糖 HP:0001985
- 低体温 HP:0002045
- 黄疸 HP:0000952
- 超重 HP:0025502
- 卵圆孔未闭 HP:0001655
- 呼吸窘迫 HP:0002098
- 小于胎龄儿 HP:0001518
- 室间隔缺损 HP:0001629
罕见 <4–1%24
- 肛门前置 HP:0001545
- 心律失常 HP:0011675
- 房室传导阻滞 HP:0001678
- 扩张型心肌病 HP:0001644
- 小脑延髓池扩大 HP:0002280
- 婴儿型肌张力减退 HP:0008947
- 高氨血症 HP:0001987
- 低钙血症 HP:0002901
- 低蛋白血症 HP:0003075
- 皮肤炎症反应 HP:0011123
- 昏睡 HP:0001254
- 巨头畸形 HP:0000256
- 代谢性酸中毒 HP:0001942
- 肌肉痉挛 HP:0003394
- 肥胖 HP:0001513
- 疼痛 HP:0012531
- 心包积液 HP:0001698
- 肺炎 HP:0002090
- QT间期延长 HP:0001657
- 心动过速 HP:0001649
- 呼吸过速 HP:0002789
- 心室纤颤 HP:0001663
- 室性心动过速 HP:0004756
- 呕吐 HP:0002013
近两年的全球研究 122L2
2024/08 起在 Europe PMC 检索所得，按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务，尚未引入。
- 2026-07Comparison of methods for defatted human milk and nutrient composition: An experimental study
- 2026-05病例报告Expanding the Mutational Spectrum of <i>ACADVL</i>: Integrative Characterization of the p.Ser72Phe Variant in Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
- 2026-05开放获取Expanding the Mutational Spectrum of ACADVL: Integrative Characterization of the p.Ser72Phe Variant in Very Long-Chain Acyl-CoA Dehydrogenase Deficiency
- 2026-05开放获取Comparison of Four Screening Markers [(C16 + C18:1)/C2, C14/C3, C12/C0, and C12/C2] for Carnitine Palmitoyltransferase II Deficiency in the Nationwide Newborn Screening Program in Japan
- 2026-05综述开放获取Newborn Screening in Saudi Arabia: Brief History, Current Practice, and Future Direction
- 2026-05开放获取Advancements and insights into newborn screening with tandem mass spectrometry in China: a comprehensive descriptive analysis (2017-2021)
- 2026-05系统综述综述开放获取Effectiveness of Riboflavin in Inherited Metabolic Diseases: A Systematic Review
- 2026-04开放获取Benchmarking genetic birth prevalence estimates against newborn screening data
- 2026-03综述开放获取Medium-Chain Triglycerides: Scientific and Regulatory Perspectives from Germany and Japan with a US Context-A Concise Review
- 2026-03开放获取Fully Automated Serum LC-MS/MS Platform and Pediatric Reference Intervals for Organic Acids, Amino Acids, and Acylcarnitines in Children (Ages 0-6 Years): Toward Quantitative Diagnosis of Inborn Errors of Metabolism
- 2026-03开放获取Current Status of Newborn Screening in Southeastern and Central Europe
- 2026-03开放获取Two Years of Expanded Newborn Screening in Russia: High-Throughput Detection of Inherited Metabolic Disorders by Tandem Mass Spectrometry with Next-Generation Sequencing Confirmation
- 2026-03开放获取Direct Prediction of VLCADD Severity Using Newborn Screening Analyte Data
- 2026-02病例报告开放获取Incidental maternal glutaric aciduria type I detection through newborn screening: A case report
- 2026-02综述开放获取Lipid droplet-associated proteins: Roles in cardiovascular diseases
- 2026-02开放获取Impact of COVID-19 infection in patients with inherited metabolic diseases: a National Multicenter Study from the French IMDs Healthcare Network for Rare Diseases
- 2026-02开放获取The Impact of Nutritional Management on Fat-Soluble Nutrient Status in Patients with Fatty Acid Oxidation Disorders: A Cross-Sectional Study
- 2026-02开放获取RPLC- and HILIC-based non-targeted metabolomics workflow for blood microsamples
- 2026-02综述The imperative for national legislation on rare diseases in China: A policy review and call to action
- 2026-02综述Foods for special medical purposes for the dietary therapy of rare diseases: Current status and future prospects
境外已获批用于本病的药物 0L2
欧盟与美国均未检索到已获批用于本病的药物。
已获孤儿药资格、尚未获批的在研药物（1 项）
孤儿药资格只是一种监管身份——它意味着监管机构认可这是罕见病用药并给予研发激励，不代表这个药已被证明有效，也不代表将来一定能上市。绝大多数最终不会成药。列在这里是为了看清有哪些方向正在被尝试。
- triheptanoin欧盟2015-06-19Treatment of very long-chain acyl-CoA dehydrogenase deficiency官方记录
数据来自欧洲药品管理局（EMA）的药品与孤儿药资格公开导出表，以及美国 FDA 孤儿药资格数据库。两边口径不同：欧盟一侧取的是当前状态仍为「已授权」的药品；美国一侧记录的是「曾获批准」这一事实，FDA 的公开表不追踪药物此后是否退市（例如 Relyvrio 于 2024 年撤市，表中仍记为已获批）。请以官方记录页为准。
中国境外的在招试验 4L2
这些试验在中国没有研究中心，通常无法直接报名——入组一般要求在当地居住并接受随访。列在这里是因为它另有用处：看清楚全世界正在试哪些药、做到了哪一期、由谁在做。把药名和 NCT 编号记下来去问主治医生，或据此进一步查该药是否已在境外获批、是否有拓展性用药（expanded access）通道。
以色列1美国1奥地利1德国1意大利1
共 4 项。
- 招募中NCT06017869Evaluate the Safety and Therapeutic Effects of a Single Intravenous Infusion (IV) of Autologous CD34+ Cells Enriched With Allogenic Placenta-derived Mitochondria in Patients With a Diagnosis of Pearson Syndrome (PS)以色列
- 招募中NCT04602325Systemic Biomarkers of Brain Injury From Hyperammonemia美国
- 招募中NCT05554835Global Registry and Natural History Study for Mitochondrial Disorders奥地利、德国、意大利
- 可获取（拓展性用药）NCT03773770Expanded Access to Triheptanoin
外部标识与链接
发现这一页有错误？告诉我 · 邮件主题会自动带上本页的 ORPHA 编号
本页数据来源
- 疾病定义、同义词、基因、表型、流行病学：Orphanet（CC BY 4.0）
- 中文病名：Orphanet 中文包，冻结于 2020-06-01
- 表型中文标签：HPO 简体中文翻译（CHPO 上游成果）